The 1^st product, EpiFaith, is a safety solution for epidural anesthesia. By transforming the subjective tactile feeling into the objective visual signal, EpiFaith has been recognized as a reliable product for a safer localization into the epidural space. The clinical benefit of EpiFaith can be translated into substantial cost-reduction for the healthcare organizations. By ceasing the accidental dural puncture, additional admission time, additional blood patch procedure and the risk of permanent paralysis, EpiFaith can help decrease the extra medical cost of $56-93 (USD) averagely for each patient. The product is now in its early launch status, being trialed and early adopted in several renowned hospitals in the U.S. and Europe.

The same tech is now being applied to another critical care procedure, central venous catheterization. The second product on the pipeline, EpiFaith CV, is a visual indicator that helps intensivists identify the arrival of vein/ artery in an easy and reliable manner. With the auto-aspiration and pressure sensing mechanism inside, EpiFaith CV is changing the blindly-accesses procedure into a fast and accurate one. EpiFaith CV is now under the final review and expected to be CE-marked (MDR) and FDA cleared in Q4, 2021.